Jane Street Group LLC Sells 22,212 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Jane Street Group LLC lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 41.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,793 shares of the company’s stock after selling 22,212 shares during the period. Jane Street Group LLC owned about 0.07% of Enliven Therapeutics worth $786,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Quest Partners LLC boosted its position in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics in the 3rd quarter worth approximately $256,000. Verition Fund Management LLC bought a new stake in Enliven Therapeutics during the 3rd quarter worth approximately $271,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the 2nd quarter valued at $322,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ELVN. BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Finally, Robert W. Baird raised their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $23.90 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -12.58 and a beta of 1.02. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The stock has a fifty day moving average of $25.09 and a 200-day moving average of $24.28.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 2,730 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $27.50, for a total transaction of $75,075.00. Following the completion of the sale, the chief executive officer now owns 1,033,793 shares in the company, valued at approximately $28,429,307.50. The trade was a 0.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 3,350 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $22.15, for a total value of $74,202.50. The disclosure for this sale can be found here. Insiders have sold a total of 92,853 shares of company stock worth $2,577,630 over the last 90 days. Insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.